Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.
about
Perforin-low memory CD8+ cells are the predominant T cells in normal humans that synthesize the beta -chemokine macrophage inflammatory protein-1betaAn improved microtiter assay for evaluating anti-HIV-1 neutralizing antibodies from sera or plasmaTissue-resident memory T cellsThe thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitroLong-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccinePandemic HIV-1 Vpu overcomes intrinsic herd immunity mediated by tetherin.A comparison of elasticities of viral levels to specific immune response mechanisms in human immunodeficiency virus infection.Recognition of HIV-1 peptides by host CTL is related to HIV-1 similarity to human proteins.HIV-1 group M conserved elements vaccine.Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads.A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys.Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS.Infection with HIV-1.Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challengeAnti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiencyEnhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genesIntrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replicationSimian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.Use of major histocompatibility complex class I/peptide/beta2M tetramers to quantitate CD8(+) cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeysThe simian immunodeficiency virus envelope glycoprotein contains two epitopes presented by the Mamu-A*01 class I molecule.Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaquesLimited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection.Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeysReduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccinationExpression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infectionWeak anti-HIV CD8(+) T-cell effector activity in HIV primary infectionA human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primatesImmunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunityHV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmissionComparison of human immunodeficiency virus antigens as stimulants for lymphocyte proliferation assaysPositive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis
P2860
Q24555821-EBA3EB5D-638E-4671-B9FA-324C011A648EQ24807239-A6CB9802-9D37-4A0E-87BC-528E23280759Q26829804-D90DCC5D-A139-4AD2-862B-81EEEE390D52Q28343837-C38E0619-D04C-40C1-9DB2-168CF72FC766Q28743435-51F72481-2790-40C5-A5D0-8DFA2388EFBDQ30376824-8719D56D-4475-4D7E-AE9B-76B564E0D6A0Q30596957-282ABFCA-C9D4-490B-A6C7-8E40BCC8F23FQ33296987-0FDE9879-0110-464F-9E1F-9103D704F76AQ33308246-77C03E52-C384-4397-B560-C428043A8BC8Q33313878-051928FB-C2B7-41F2-B29C-56A4B1877AB6Q33603919-21C0A78D-08F4-4242-9E49-91C032CEE433Q33642024-D9E7757E-FEE1-4072-8D18-48485245FE3DQ33645053-BE6FF30C-45D2-43A4-AF8A-7800B40815CAQ33690988-E3304333-2978-4F63-9D8A-2EB9483C4A75Q33717525-4DFAAD55-E549-4A52-8D01-65306ABE7505Q33785371-F89E114B-CC6C-4B5C-BD77-2D12605EFC1DQ33792479-E11F1EA5-3B66-4BD2-B99E-CA28AB4C3217Q33799497-7254B169-D243-4A58-B4B7-0FA42EB7934AQ33803446-D655942C-C611-482D-92D8-978EFAB96811Q33806715-2D261C4A-2A27-487B-AF14-1CFCD1558A70Q33811112-C3E5BF9E-B917-4BDF-86BF-530D6DCE8EE8Q33811266-729B575F-C6BF-49E5-A83B-52CCA3E38491Q33813926-336A2833-6743-44C9-903B-8F232195D316Q33815102-827179AA-8F01-4FBB-84BA-C42AD349F4B3Q33818964-0E97EE7E-6FE4-495D-BE90-73DFC245AE43Q33822789-9BBEEDDC-C9E9-4866-B699-2758EE31051FQ33829574-24DF837F-9261-45A5-8A3B-52E69FE7E64EQ33843340-83BC9943-B2E3-4773-8FC3-A2ED48CC0BA8Q33844334-C1DE4184-92BE-483F-97F5-71B9319F47D5Q33850510-3ED5E03C-B34C-43B9-9F42-06562B6D7280Q33850904-6D545859-BA88-496C-80E2-302DAA264208Q33851802-29FF5CFB-53E4-4EE4-9A13-F0D8710FAEEFQ33854615-977FB486-FA1A-47C4-9FCB-F042853DD2D4Q33869806-C41F001E-6014-4521-9E7F-AA3EC5F550D0Q33880339-4C87E26D-9CDA-4658-AAD2-C937532564E3Q33883854-A89EF0E3-57AD-4098-9CD9-3D6B4F920A28Q33908767-6951F4C7-ED93-499E-A9CA-135163D980A7Q33936741-059BE4A2-81C2-40D4-AA07-FE9EB5265465Q33943064-AFFB2112-E041-44EA-A66C-28EBDC2D7B5AQ34010283-334C094C-7E0A-4410-AFAD-DDE1E31DAA90
P2860
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Cytotoxic-T-cell responses, vi ...... ciency virus type 1 infection.
@en
Cytotoxic-T-cell responses, vi ...... ciency virus type 1 infection.
@nl
type
label
Cytotoxic-T-cell responses, vi ...... ciency virus type 1 infection.
@en
Cytotoxic-T-cell responses, vi ...... ciency virus type 1 infection.
@nl
prefLabel
Cytotoxic-T-cell responses, vi ...... ciency virus type 1 infection.
@en
Cytotoxic-T-cell responses, vi ...... ciency virus type 1 infection.
@nl
P2093
P1476
Cytotoxic-T-cell responses, vi ...... ciency virus type 1 infection.
@en
P2093
P304
P356
10.1056/NEJM199710303371803
P407
P577
1997-10-01T00:00:00Z